Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To establish a model for predicting the disease-specific survival (DSS) of patients with oral squamous cell carcinoma (OSCC).
Methods: Patients diagnosed with OSCC from the Surveillance, Epidemiology, and End Results (SEER) database were enrolled and randomly divided into development (n = 14,495) and internal validation cohort (n = 9625). Additionally, a cohort from a hospital located in Southeastern China was utilized for external validation (n = 582).
Results: TNM stage, adjuvant treatment, surgery, tumor sites, age, grade, and gender were used for RSF model construction based on the development cohort. The effectiveness of the model was confirmed through time-dependent ROC curves in different cohorts. The risk score exhibited an almost exponential increase in the hazard ratio of death due to OSCC. In development, internal, and external validation cohorts, the prognosis was significantly worse for patients in groups with higher risk scores (all log-rank P < 0.05).
Conclusion: Based on RSF, a high-performance prediction model for OSCC prognosis was created and verified in this study.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00405-023-08087-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Factors and Disease-Specific Outcomes Associated With Treatment Delays in Osteosarcoma: A Population-Based Retrospective Cohort Study.
J Surg Oncol
September 2025
School of Medicine, Creighton University; Omaha, Nebraska, USA.
Introduction: Time to initiation of therapy in oncological care is an influential factor in disease progression and survival outcomes in many cancer types. We aim to identify factors associated with delayed time to treatment (TTT) in high-grade osteosarcoma and its relationship to disease-specific survival (DSS).
Methods: The SEER database was queried for biopsy-confirmed cases of high-grade osteosarcoma between 2000 and 2021 using ICD-O-3 histology codes 9180/3-9194/3 and primary site codes C40.
Disease-Specific Mortality in Patients With Acromegaly Treated With Pegvisomant: An ACROSTUDY Analysis.
Endocr Connect
September 2025
Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Objective: Characterize disease-specific mortality rates in patients with acromegaly on pegvisomant and identify pertinent risk factors, including on-therapy insulin-like growth factor I (IGF-I) levels.
Design: Retrospective cohort analysis of ACROSTUDY, a global surveillance study of patients with acromegaly receiving pegvisomant.
Methods: Cumulative incidence function to estimate disease-specific mortality and regression analyses to characterize risk factors.
AARS1 Implicates Malignancy and Immune Infiltration in Head and Neck Squamous Cell Carcinoma, Serving as a Prognostic Predictor.
J Oral Pathol Med
September 2025
Department of Oral Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: The aberrant expression of AARS1 has been linked to tumor progression in various cancers. However, its role and underlying mechanisms in head and neck squamous cell carcinoma (HNSCC) remain unclear.
Methods: We validated AARS1 expression using databases and cell lines.
Primary Cutaneous CD4+ Small Medium T Cell Lymphoproliferative Disorder - 20 years of experience from a specialist centre.
Br J Dermatol
September 2025
Clinical Oncology, Guy's and Thomas' NHS Foundation Trust, London, uk.
Background: Primary Cutaneous CD4+ Small Medium T Cell Lymphoproliferative Disorder (PCSM-TLPD) is a rare subtype of indolent lymphoproliferative disease. The treatment, investigations and follow-up protocol are being re-evaluated.
Objective: To use our service evaluation to understand the presentation, response rate, relapse rate, treatment variation, progression free and overall survival of our cohort.
Improving oncological outcomes for pelvic bone sarcomas: Is it possible?
Eur J Surg Oncol
August 2025
Royal Orthopaedic Hospital, Birmingham, United Kingdom.
Introduction: Pelvic bone sarcomas are rare, heterogeneous malignancies that present significant diagnostic and therapeutic challenges. Despite advances in imaging, surgical navigation, and multidisciplinary care, it remains unclear whether these innovations have improved outcomes across all histiotypes.
Material And Methods: We conducted a retrospective cohort study of 475 patients surgically treated for primary pelvic bone sarcomas between 2003 and 2022.